Antineoplastic Paclitaxel CAS 33069-62-4 Raw Materials Powder

CAS: 33069-62-4

MF: C47H51NO14

Specification​: 99% min Paclitaxel Powder

Sample: Paclitaxel Powder

Brand: Henrikang

Appearance: White Powder

Storage: Cool Dry Place

Shelf Life: 2 Years

Test Method: HPLC

MADE IN CHINA Store:https://henrikang.en.made-in-china.com/

Paclitaxel Powder Usage and Synthesis .

Paclitaxel is a monomeric diterpenoid extracted from the bark of the natural plant, Euphorbia latifolia, which is a complex secondary metabolite and is the only drug known to promote the polymerization of microtubules and stabilize the polymerized microtubules. Isotope tracing showed that paclitaxel only bound to polymerized microtubules and did not react with unpolymerized microtubule protein dimers.

The accumulation of microtubules in cells exposed to paclitaxel interferes with various cellular functions, especially the arrest of cell division in mitosis, and blocks normal cell division. Through II-III clinical studies, paclitaxel is mainly used in ovarian and breast cancers, but it is also effective in lung cancer, colorectal cancer, melanoma, head and neck cancer, lymphoma and brain tumor.

Paclitaxel Powder is a natural compound, Paclitaxel Raw Materials is a diterpenoid extracted from the bark and leaves of the yew tree. Paclitaxel CAS 33069-62-4 has a variety of biological activities such as Anti-cancer and immunomodulation, and is an important Anti-cancer drug. Paclitaxel Powder can interfere with the mitotic process of tumor cells, thus preventing cell division and proliferation and causing tumor cell death. Currently, paclitaxel has been widely used in the treatment of breast cancer, ovarian cancer, lung cancer, colon cancer and many other cancers.

Applications of Paclitaxel Powder ：

Paclitaxel Powder is effective in the treatment of ovarian cancer, ovarian cancer that is resistant to platinum, breast cancer, prostate cancer, head and neck cancer, esophageal cancer, germ cell tumors, endometrial cancer, lymphoma, bladder cancer, upper gastrointestinal tract cancer, small cell and non-small cell lung cancer.

Production method of Paclitaxel Powder：

It is a natural product isolated and purified from the bark, woody roots, leaves, shoots and seedlings of Yew tree, with the highest content in the bark. It is classified under the subphylum Gymnospermae, class Pinaceae, order Yew, family Redbudaceae, and genus Redbud.

The family contains 5 genera and 23 species, and there are 4 genera and 12 species and 1 variety in China, which are Tibetan red bean fir or Himalayan red bean fir (TaxuswallichinanaZucc.), Yunnan red bean fir (Taxusyunnanensis), southern red bean fir (Taxuschinensisvat. Mairei) and northeastern red bean fir ( Taxuscuspidata).

It is distributed in the mountainous areas of Tibet, Yunnan, Guizhou, Sichuan, Guangxi, Guangdong, Hunan, Hubei, Jiangxi, Fujian, Zhejiang, Anhui, Henan, Shanxi, Shaanxi, Gansu, and Jilin. It is extracted from the bark or leaves of the genus Redbud. Redbud bark or leaves were shade dried, ground finely, and extracted with 95% ethanol.

The extract is concentrated to dryness, and the residue is mixed with water and dichloromethane and stirred. The organic layer was separated by standing, and the aqueous layer was extracted several times with dichloromethane. The extracts and organic layer were combined and concentrated to dryness. The residue was dissolved in ethyl acetate-methanol (3:1), mixed with fresh diatomaceous earth, and the solvent was evaporated under reduced pressure.

The remaining powder was subjected to rapid column chromatography, eluting first with hexane and then with dichloromethane. The latter was collected and the dichloromethane was evaporated under reduced pressure. The residue was dissolved in ethyl acetate and chromatographed on 70 sets (3-4 each) of medium-pressure fast columns packed with silica gel, eluting with different ratios of hexane-acetone. The fraction containing the product was collected and concentrated.

The residue was then purified by medium-pressure fast chromatography columns equipped with silica gel and eluted with different ratios of methanol-dichloromethane. The product-containing fraction was collected and concentrated under reduced pressure to in. The residue was then separated by preparative high performance liquid chromatography, and the obtained product was recrystallized twice more with aqueous methanol to obtain the pure paclitaxel. Yield: 0.028% for bark and 0.0088% for leaves.

Yield: 93.3% for bark, 88% for leaves. Melting point 212-214°C, [α]D20-49° (1%, chloroform). The stem bark of Chinese red fir was crushed, shade dried, and soaked in 1% citric acid aqueous solution for 24 h before starting to percolate. The percolate was extracted with dichloromethane, and the extract was dried, concentrated and vacuum dried.

Two times of column chromatography was performed with silica gel, and the collected effluent contained paclitaxel and trichothecene. Based on the difference of their side chain structures, they were dissolved in carbon tetrachloride with bromine, and only the trichothecene was brominated, and then the effluent containing only paclitaxel was obtained by column chromatography with silica gel, and after treatment, paclitaxel boutique was obtained with 99.19%, 4.5×10-5 yield and 70% recovery.

A little history of the development of Paclitaxel Powder:

In 1963, American chemists M.C. Wani and Monre E. Wall first isolated a crude extract of paclitaxel from the bark and wood of a species of tree called PacificYew, which grows in the great forests of the western United States. In screening experimental redwoods, Wani and Wall found that the crude extract of paclitaxel was highly active against murine tumor cells in isolated cultures, and began to isolate this active ingredient. Due to the extremely low levels of this active ingredient in the plant

Only in 1971, in collaboration with Andre T. McPhail, a professor of chemistry at Duke University, they determined the chemical structure of the active ingredient, a tetracyclic diterpene, by x-ray analysis and named it taxol.

In 1971, paclitaxel was discovered in redbud and found to have a unique anti-cancer mechanism.

In 1992, the U.S. government transferred the patent to Schweppes and paclitaxel was introduced.

In 1994, paclitaxel became the world's top-selling anti-cancer drug in the world.

In 2000, the sales of paclitaxel reached 10 billion (later not further increased by the supply of raw materials)

In 2002, the central government issued a document strictly prohibiting the cutting of wild red fir and encouraging artificial cultivation.

In 2004, the patent of Schweppes expired, and more pharmaceutical companies around the world were involved in the production of paclitaxel.

In 2004, Huayuan started the operation of the red fir project and prepared to build a direct paclitaxel refining and processing plant, aiming to become the largest red fir base in China and even in Asia.

In 2005, the central government issued another document to conduct a nationwide survey of red fir resources and encourage planting.

In 2005, this project accepted investment from individual investors.